Header Logo

Reina Haque

Concepts (318)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
31
2022
949
5.210
Why?
Prostatic Neoplasms
13
2022
262
2.890
Why?
Tamoxifen
9
2016
56
2.630
Why?
Cancer Survivors
4
2022
83
2.350
Why?
Neoplasm Recurrence, Local
14
2024
244
2.110
Why?
Aromatase Inhibitors
6
2016
32
2.090
Why?
Survivors
10
2022
149
1.920
Why?
Antineoplastic Agents, Hormonal
7
2017
63
1.710
Why?
Humans
78
2024
17611
1.480
Why?
Aged
54
2024
6095
1.470
Why?
Neoplasms
3
2023
438
1.410
Why?
Androgen Antagonists
5
2017
17
1.400
Why?
Middle Aged
55
2024
7911
1.330
Why?
Cardiovascular Diseases
6
2017
598
1.190
Why?
Female
46
2024
12608
1.110
Why?
Depressive Disorder
2
2022
222
1.060
Why?
Proportional Hazards Models
13
2021
709
1.050
Why?
California
21
2023
2284
1.040
Why?
Neoplasms, Second Primary
2
2016
29
0.940
Why?
CA-125 Antigen
2
2020
6
0.890
Why?
Health Maintenance Organizations
4
2017
417
0.870
Why?
Membrane Proteins
2
2020
38
0.870
Why?
Ovarian Neoplasms
2
2020
49
0.840
Why?
Adult
31
2022
7598
0.830
Why?
Aged, 80 and over
20
2021
1900
0.820
Why?
Neoplasm Staging
13
2016
325
0.810
Why?
Paroxetine
2
2015
23
0.770
Why?
Male
38
2024
10008
0.740
Why?
Risk Factors
19
2021
3325
0.730
Why?
Health Services Accessibility
1
2023
289
0.710
Why?
Retrospective Studies
13
2023
2447
0.710
Why?
Depression
3
2022
502
0.700
Why?
Cohort Studies
20
2022
2570
0.680
Why?
Insurance, Health
1
2021
181
0.670
Why?
Obesity
4
2021
837
0.660
Why?
Healthcare Disparities
1
2021
201
0.630
Why?
Endometrial Neoplasms
2
2015
35
0.620
Why?
Patient Compliance
3
2020
298
0.610
Why?
Arrhythmias, Cardiac
1
2017
32
0.580
Why?
Protein Kinase Inhibitors
1
2017
3
0.570
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2017
2
0.570
Why?
Prognosis
11
2022
606
0.530
Why?
Sigmoidoscopy
2
2007
65
0.530
Why?
Algorithms
4
2020
233
0.520
Why?
Antidepressive Agents, Second-Generation
1
2015
28
0.520
Why?
Pathology Department, Hospital
1
2015
3
0.500
Why?
Diphosphonates
1
2016
62
0.500
Why?
Lymphoma, Large B-Cell, Diffuse
4
2017
14
0.500
Why?
Overweight
2
2021
269
0.490
Why?
Medication Adherence
2
2017
244
0.490
Why?
Carcinoma, Intraductal, Noninfiltrating
5
2015
40
0.480
Why?
Radiotherapy, Adjuvant
4
2016
18
0.470
Why?
Biomarkers, Tumor
4
2020
142
0.450
Why?
Urinary Bladder Neoplasms
2
2024
56
0.420
Why?
Research Design
1
2015
374
0.420
Why?
Arsenic
4
2007
5
0.420
Why?
Multivariate Analysis
4
2021
568
0.410
Why?
Antidepressive Agents
2
2022
155
0.410
Why?
Social Class
3
2023
120
0.400
Why?
Follow-Up Studies
11
2024
1210
0.400
Why?
Heart Failure
1
2017
396
0.400
Why?
Inflammation
1
2012
62
0.400
Why?
Neoplasm Grading
4
2017
48
0.400
Why?
Sleep Wake Disorders
1
2012
37
0.400
Why?
Mass Screening
2
2009
661
0.390
Why?
Prostate-Specific Antigen
3
2016
75
0.390
Why?
Prospective Studies
11
2024
1267
0.380
Why?
Risk Reduction Behavior
1
2012
108
0.380
Why?
Registries
7
2021
471
0.370
Why?
Continental Population Groups
2
2009
302
0.370
Why?
Carcinoma, Ductal
1
2010
4
0.360
Why?
Socioeconomic Factors
3
2023
630
0.360
Why?
Body Mass Index
3
2013
958
0.350
Why?
Preventive Health Services
1
2012
159
0.350
Why?
Cross-Sectional Studies
10
2012
1322
0.340
Why?
Risk
6
2020
516
0.340
Why?
Electronic Health Records
1
2015
681
0.340
Why?
Comorbidity
4
2023
594
0.330
Why?
Case-Control Studies
13
2015
1115
0.330
Why?
Prostatectomy
5
2016
75
0.330
Why?
Incidence
9
2015
1255
0.320
Why?
Prostate
2
2022
28
0.320
Why?
Managed Care Programs
1
2010
325
0.300
Why?
Gonadotropin-Releasing Hormone
3
2017
10
0.300
Why?
Water Supply
3
2007
8
0.300
Why?
Environmental Exposure
4
2007
116
0.300
Why?
Insurance Carriers
1
2007
6
0.290
Why?
Organizations, Nonprofit
1
2007
11
0.290
Why?
Practice Patterns, Physicians'
1
2010
330
0.290
Why?
Keratosis
2
2004
2
0.280
Why?
Salvage Therapy
2
2016
17
0.280
Why?
Colorectal Neoplasms
3
2010
613
0.270
Why?
Treatment Outcome
8
2024
1259
0.270
Why?
Longitudinal Studies
3
2022
710
0.250
Why?
Young Adult
6
2022
2427
0.250
Why?
Survival Rate
4
2014
260
0.250
Why?
HIV Infections
3
2017
694
0.250
Why?
Ethnic Groups
2
2021
485
0.250
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
3
2015
171
0.240
Why?
Receptor, ErbB-2
2
2016
46
0.240
Why?
Odds Ratio
6
2017
671
0.240
Why?
Sensitivity and Specificity
4
2020
304
0.240
Why?
Mitomycin
1
2024
4
0.240
Why?
Isothiocyanates
1
2024
8
0.240
Why?
BCG Vaccine
1
2024
7
0.240
Why?
Logistic Models
7
2013
926
0.220
Why?
Ultrasonography
2
2020
35
0.220
Why?
Hyperpigmentation
1
2003
1
0.220
Why?
Early Detection of Cancer
3
2020
501
0.220
Why?
Colonoscopy
1
2005
251
0.210
Why?
Lower Urinary Tract Symptoms
2
2013
13
0.210
Why?
Electronic Nicotine Delivery Systems
1
2022
32
0.200
Why?
Breast
1
2022
84
0.200
Why?
United States
7
2015
3956
0.200
Why?
Hallucinogens
1
2022
23
0.200
Why?
Hip Fractures
2
2015
67
0.200
Why?
Arsenic Poisoning
3
2007
3
0.200
Why?
Feasibility Studies
2
2020
114
0.190
Why?
Sleep
1
2021
58
0.190
Why?
Chemotherapy, Adjuvant
4
2015
70
0.190
Why?
Depressive Disorder, Major
1
2022
124
0.190
Why?
Mammography
3
2012
169
0.180
Why?
Cannabis
1
2022
78
0.180
Why?
Erectile Dysfunction
2
2011
24
0.180
Why?
Watchful Waiting
1
2020
18
0.170
Why?
Wine
2
2010
18
0.170
Why?
Carcinoma in Situ
2
2009
17
0.170
Why?
Adolescent
5
2017
3651
0.170
Why?
Survival Analysis
2
2017
215
0.170
Why?
Pilot Projects
1
2020
218
0.160
Why?
Carcinoma, Ductal, Breast
2
2009
53
0.160
Why?
India
7
2012
13
0.160
Why?
Kaplan-Meier Estimate
3
2015
129
0.160
Why?
Receptors, Estrogen
2
2016
51
0.160
Why?
Neoplasm Invasiveness
5
2024
78
0.160
Why?
Vaccination
1
2023
635
0.150
Why?
Disease-Free Survival
2
2015
57
0.150
Why?
Cell Cycle Proteins
2
2015
6
0.150
Why?
Apoptosis
2
2015
10
0.150
Why?
Leuprolide
1
2017
2
0.150
Why?
Goserelin
1
2017
2
0.150
Why?
Imidazolidines
1
2017
2
0.150
Why?
Flutamide
1
2017
3
0.150
Why?
Anilides
1
2017
3
0.150
Why?
Tosyl Compounds
1
2017
3
0.150
Why?
Exercise
1
2022
489
0.150
Why?
Diabetes Mellitus
2
2014
487
0.150
Why?
Nitriles
1
2017
7
0.150
Why?
Skin Diseases
3
2005
10
0.150
Why?
Antineoplastic Agents
2
2015
59
0.150
Why?
Hospitalization
1
2023
797
0.150
Why?
Clinical Laboratory Services
1
2016
1
0.140
Why?
Time Factors
6
2013
1086
0.140
Why?
Delivery of Health Care, Integrated
2
2021
531
0.140
Why?
Water Pollutants, Chemical
2
2007
4
0.140
Why?
Medical Records
2
2008
100
0.130
Why?
Administration, Oral
1
2016
85
0.130
Why?
Disease Progression
1
2017
264
0.130
Why?
Medroxyprogesterone Acetate
1
2015
15
0.130
Why?
Immunohistochemistry
4
2017
44
0.130
Why?
T-Lymphocyte Subsets
1
2015
4
0.130
Why?
Macrophages
1
2015
4
0.130
Why?
Forecasting
1
2016
75
0.130
Why?
CD8-Positive T-Lymphocytes
1
2015
5
0.130
Why?
Health Resources
1
2015
37
0.130
Why?
Smoking
3
2022
483
0.130
Why?
Nomograms
1
2015
11
0.130
Why?
Estrogen Replacement Therapy
1
2015
99
0.130
Why?
Apoptosis Regulatory Proteins
1
2015
4
0.120
Why?
Lymphocyte Activation
1
2015
7
0.120
Why?
SEER Program
4
2017
91
0.120
Why?
Mastectomy, Segmental
2
2012
20
0.120
Why?
European Continental Ancestry Group
3
2012
529
0.120
Why?
Prevalence
6
2014
884
0.110
Why?
Oncogene Proteins, Fusion
1
2013
3
0.110
Why?
Trans-Activators
1
2013
8
0.110
Why?
Health Behavior
2
2015
359
0.110
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2011
65
0.110
Why?
Predictive Value of Tests
1
2014
351
0.110
Why?
Men's Health
2
2009
20
0.100
Why?
Epstein-Barr Virus Infections
1
2012
4
0.100
Why?
Life Style
2
2012
332
0.100
Why?
Dose-Response Relationship, Drug
3
2015
129
0.100
Why?
Lymphoma, AIDS-Related
1
2012
18
0.100
Why?
Fractures, Bone
1
2013
91
0.100
Why?
Gene Expression Regulation, Neoplastic
1
2012
51
0.100
Why?
Clinical Trials as Topic
1
2012
130
0.100
Why?
Acquired Immunodeficiency Syndrome
1
2012
63
0.100
Why?
Asian Continental Ancestry Group
1
2012
90
0.100
Why?
Health Care Surveys
1
2012
230
0.090
Why?
Health Status
2
2009
298
0.090
Why?
Mammary Glands, Human
1
2010
8
0.090
Why?
Medical Audit
1
2010
38
0.090
Why?
Prostatitis
1
2010
5
0.090
Why?
Massachusetts
1
2010
93
0.090
Why?
Health Status Disparities
1
2011
146
0.090
Why?
Sexually Transmitted Diseases
1
2010
54
0.080
Why?
Family Characteristics
1
2009
54
0.080
Why?
Confounding Factors (Epidemiology)
1
2009
86
0.080
Why?
Educational Status
1
2009
200
0.080
Why?
Bias
1
2009
102
0.080
Why?
Enzyme Inhibitors
1
2008
3
0.080
Why?
5-alpha Reductase Inhibitors
1
2008
7
0.080
Why?
Quality of Life
1
2012
507
0.080
Why?
Body Height
1
2008
62
0.080
Why?
Child
3
2022
2474
0.080
Why?
Population Surveillance
3
2016
263
0.080
Why?
Patient Education as Topic
1
2009
211
0.080
Why?
Risk Assessment
3
2020
1097
0.070
Why?
Residence Characteristics
1
2009
248
0.070
Why?
Body Weight
1
2008
219
0.070
Why?
Precancerous Conditions
1
2007
47
0.070
Why?
Fetal Development
1
2007
14
0.070
Why?
Cognition Disorders
1
2007
31
0.070
Why?
Age Factors
3
2015
917
0.070
Why?
Methionine
1
2005
5
0.070
Why?
Selenium
1
2005
4
0.070
Why?
Micronutrients
1
2005
9
0.070
Why?
beta Carotene
1
2005
17
0.070
Why?
Water
1
2005
2
0.060
Why?
Respiration Disorders
1
2005
5
0.060
Why?
Bronchiectasis
1
2005
7
0.060
Why?
Diabetes Mellitus, Type 2
1
2013
748
0.060
Why?
Surveys and Questionnaires
4
2011
1309
0.060
Why?
Automation
1
2005
24
0.060
Why?
Nutrition Disorders
1
2004
1
0.060
Why?
Skin Pigmentation
1
2004
6
0.060
Why?
Antibiotics, Antineoplastic
1
2024
7
0.060
Why?
Adjuvants, Immunologic
1
2024
15
0.060
Why?
Biopsy
2
2017
74
0.060
Why?
Proto-Oncogene Proteins c-bcl-6
2
2015
6
0.060
Why?
DNA-Binding Proteins
2
2015
29
0.060
Why?
Rural Population
1
2003
51
0.050
Why?
Leukocytes, Mononuclear
1
2022
9
0.050
Why?
Telomere
1
2022
19
0.050
Why?
Drug Administration Schedule
2
2015
98
0.050
Why?
Diet
1
2024
365
0.050
Why?
Tumor Burden
2
2013
19
0.050
Why?
Ovary
1
2020
3
0.050
Why?
BRCA2 Protein
1
2020
5
0.050
Why?
BRCA1 Protein
1
2020
6
0.050
Why?
Heterozygote
1
2020
26
0.050
Why?
Mutation
1
2020
128
0.040
Why?
Gene Expression Regulation
1
2017
23
0.040
Why?
ROC Curve
1
2017
77
0.040
Why?
In Situ Hybridization, Fluorescence
1
2016
14
0.040
Why?
CD4 Lymphocyte Count
1
2017
178
0.030
Why?
Biomarkers
1
2017
301
0.030
Why?
Antigens, Differentiation, Myelomonocytic
1
2015
3
0.030
Why?
Antigens, CD
1
2015
5
0.030
Why?
Hysterectomy
1
2015
29
0.030
Why?
Severity of Illness Index
2
2009
454
0.030
Why?
Forkhead Transcription Factors
1
2015
6
0.030
Why?
CD4-Positive T-Lymphocytes
1
2015
13
0.030
Why?
Reproducibility of Results
1
2016
381
0.030
Why?
Double-Blind Method
1
2015
155
0.030
Why?
Proliferating Cell Nuclear Antigen
1
2015
3
0.030
Why?
Interferon Regulatory Factors
1
2015
3
0.030
Why?
Protein Kinase C beta
1
2015
3
0.030
Why?
Hyaluronan Receptors
1
2015
4
0.030
Why?
Proto-Oncogene Proteins c-myc
1
2015
5
0.030
Why?
Immunoglobulin M
1
2015
8
0.030
Why?
Women's Health
1
2015
200
0.030
Why?
Postmenopause
1
2015
241
0.030
Why?
Orchiectomy
1
2014
6
0.030
Why?
Neoplasms, Hormone-Dependent
1
2014
8
0.030
Why?
Michigan
1
2014
26
0.030
Why?
Neoadjuvant Therapy
1
2014
13
0.030
Why?
Myocardial Infarction
1
2015
238
0.030
Why?
Mortality
1
2014
117
0.030
Why?
Transcriptional Regulator ERG
1
2013
3
0.030
Why?
Cause of Death
1
2014
181
0.030
Why?
Positive Regulatory Domain I-Binding Factor 1
1
2012
3
0.030
Why?
Ki-1 Antigen
1
2012
3
0.030
Why?
B7-1 Antigen
1
2012
3
0.030
Why?
LIM Domain Proteins
1
2012
3
0.030
Why?
In Situ Hybridization
1
2012
6
0.030
Why?
Repressor Proteins
1
2012
13
0.030
Why?
Adaptor Proteins, Signal Transducing
1
2012
15
0.030
Why?
Herpesvirus 4, Human
1
2012
6
0.030
Why?
NF-kappa B
1
2012
11
0.030
Why?
Proto-Oncogene Proteins
1
2012
32
0.030
Why?
Patient Selection
1
2012
190
0.020
Why?
Asian Americans
1
2011
176
0.020
Why?
Lymphatic Metastasis
1
2009
29
0.020
Why?
Acculturation
1
2009
20
0.020
Why?
Mastectomy
1
2009
36
0.020
Why?
Language
1
2009
51
0.020
Why?
Hispanic Americans
1
2011
404
0.020
Why?
Combined Modality Therapy
1
2009
145
0.020
Why?
Data Interpretation, Statistical
1
2009
77
0.020
Why?
Dutasteride
1
2008
1
0.020
Why?
Azasteroids
1
2008
1
0.020
Why?
Finasteride
1
2008
1
0.020
Why?
African Continental Ancestry Group
1
2009
162
0.020
Why?
Adrenergic alpha-Antagonists
1
2008
9
0.020
Why?
Propensity Score
1
2009
85
0.020
Why?
Recurrence
1
2009
186
0.020
Why?
Prostatic Hyperplasia
1
2008
24
0.020
Why?
African Americans
1
2011
472
0.020
Why?
Health Services Research
1
2009
231
0.020
Why?
Receptors, Progesterone
1
2008
50
0.020
Why?
Confidence Intervals
1
2008
237
0.020
Why?
Age Distribution
1
2008
246
0.020
Why?
Intelligence Tests
1
2007
4
0.020
Why?
Exanthema
1
2007
7
0.020
Why?
Epidemiological Monitoring
1
2007
25
0.020
Why?
Environmental Monitoring
1
2007
26
0.020
Why?
Statistics, Nonparametric
1
2005
50
0.020
Why?
Respiratory Function Tests
1
2005
32
0.020
Why?
Chi-Square Distribution
1
2005
154
0.020
Why?
Alcohol Drinking
1
2008
368
0.020
Why?
Prenatal Exposure Delayed Effects
1
2007
160
0.020
Why?
Nutritional Status
1
2004
30
0.010
Why?
Tomography, X-Ray Computed
1
2005
205
0.010
Why?
Health Surveys
1
2004
260
0.010
Why?
Child, Preschool
1
2007
1409
0.010
Why?
Pregnancy
1
2007
1494
0.010
Why?
Concepts (318)
Explore
_
Co-Authors (21)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_
-->

© 2025 Kaiser Permanente